Literature DB >> 20534737

GDF-15 contributes to proliferation and immune escape of malignant gliomas.

Patrick Roth1, Markus Junker, Isabel Tritschler, Michel Mittelbronn, Yvonne Dombrowski, Samuel N Breit, Ghazaleh Tabatabai, Wolfgang Wick, Michael Weller, Jörg Wischhusen.   

Abstract

PURPOSE: Growth and differentiation factor (GDF)-15 is a member of the transforming growth factor (TGF)-beta family. GDF-15 is necessary for the maintenance of pregnancy but has also been linked to other physiologic and pathologic conditions. EXPERIMENTAL
DESIGN: The expression of GDF-15 in glioma cell lines was assessed by quantitative reverse transcriptase-PCR and immunoblot. GDF-15 levels in situ and in the peripheral blood of glioma patients were examined by immunohistochemistry and enzyme-linked immunosorbent assay, respectively. The effects of short hairpin RNA-mediated GDF-15 inhibition on proliferation and immunogenicity of SMA-560 glioma cells were investigated by [methyl-(3)H]thymidine incorporation and immune-mediated target cell lysis. The impact of GDF-15 on glioma growth in vivo was assessed in syngeneic mice.
RESULTS: GDF-15 is expressed by gliomas of different WHO grades as assessed by immunohistochemistry. The high expression of GDF-15 in tumor tissue translates into elevated GDF-15 serum levels in glioblastoma patients compared with healthy controls. GDF-15 mRNA and protein are also detectable in human and mouse glioma cells in vitro. Silencing of GDF-15 by RNA interference reduces the proliferation of malignant glioma cells. Immunologically, the depletion of glioma-derived GDF-15 enhances the susceptibility of mouse glioma cells towards syngeneic natural killer cells and splenocytes. This results in a reduced in vivo tumorigenicity and increased T-cell infiltration of GDF-15-deficient glioma cells in syngeneic mice.
CONCLUSIONS: Although previous studies focusing on ectopic overexpression of GDF-15 have proposed unclear or antitumorigenic effects of GDF-15 in glioma cells, we here show that GDF-15 at endogenous levels contributes to proliferation and immune escape of malignant gliomas in an immunocompetent host. (c) 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20534737     DOI: 10.1158/1078-0432.CCR-10-0705

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  56 in total

1.  Morphological effects on expression of growth differentiation factor 15 (GDF15), a marker of metastasis.

Authors:  Koh Meng Aw Yong; Yu Zeng; Donald Vindivich; Jude M Phillip; Pei-Hsun Wu; Denis Wirtz; Robert H Getzenberg
Journal:  J Cell Physiol       Date:  2014-03       Impact factor: 6.384

2.  Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression.

Authors:  Thomas J Rogers; Jessica L Christenson; Lisa I Greene; Kathleen I O'Neill; Michelle M Williams; Michael A Gordon; Travis Nemkov; Angelo D'Alessandro; Greg D Degala; Jimin Shin; Aik-Choon Tan; Diana M Cittelly; James R Lambert; Jennifer K Richer
Journal:  Mol Cancer Res       Date:  2018-09-13       Impact factor: 5.852

3.  Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells.

Authors:  Jayashree P Joshi; Nicole E Brown; Samantha E Griner; Rita Nahta
Journal:  Biochem Pharmacol       Date:  2011-07-23       Impact factor: 5.858

4.  Microfluidics in Malignant Glioma Research and Precision Medicine.

Authors:  Meghan Logun; Wujun Zhao; Leidong Mao; Lohitash Karumbaiah
Journal:  Adv Biosyst       Date:  2018-04-02

Review 5.  Vaccine-based immunotherapeutic approaches to gliomas and beyond.

Authors:  Michael Weller; Patrick Roth; Matthias Preusser; Wolfgang Wick; David A Reardon; Michael Platten; John H Sampson
Journal:  Nat Rev Neurol       Date:  2017-05-12       Impact factor: 42.937

Review 6.  Molecular alterations in glioblastoma: potential targets for immunotherapy.

Authors:  Azizul Haque; Naren L Banik; Swapan K Ray
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

7.  Distinct response to GDF15 knockdown in pediatric and adult glioblastoma cell lines.

Authors:  Mirella Baroni; Suely Kazue Nagahashi Marie; Paola Fernanda Fedatto; Augusto Faria Andrade; Veridiana Kill Suazo; Gustavo Alencastro Veiga Cruzeiro; Rosane de Paula Queiroz; Luiz Gonzaga Tone; Carlos Alberto Scrideli
Journal:  J Neurooncol       Date:  2018-04-18       Impact factor: 4.130

8.  P38 MAPK contributes to resistance and invasiveness of HER2- overexpressing breast cancer.

Authors:  S M Donnelly; E Paplomata; B M Peake; E Sanabria; Z Chen; R Nahta
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

Review 9.  Beyond TGFβ: roles of other TGFβ superfamily members in cancer.

Authors:  Lalage M Wakefield; Caroline S Hill
Journal:  Nat Rev Cancer       Date:  2013-05       Impact factor: 60.716

Review 10.  Concise review: growth differentiation factor 15 in pathology: a clinical role?

Authors:  Jill Corre; Benjamin Hébraud; Philippe Bourin
Journal:  Stem Cells Transl Med       Date:  2013-11-04       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.